CN114258317B - 用于治疗炎性病症的方法和组合物 - Google Patents

用于治疗炎性病症的方法和组合物 Download PDF

Info

Publication number
CN114258317B
CN114258317B CN202080058199.7A CN202080058199A CN114258317B CN 114258317 B CN114258317 B CN 114258317B CN 202080058199 A CN202080058199 A CN 202080058199A CN 114258317 B CN114258317 B CN 114258317B
Authority
CN
China
Prior art keywords
composition
peptide
inflammatory
peptides
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080058199.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN114258317A (zh
Inventor
劳拉·D·希利
劳伦特·O·莫尼耶
约翰·H·格里芬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of CN114258317A publication Critical patent/CN114258317A/zh
Application granted granted Critical
Publication of CN114258317B publication Critical patent/CN114258317B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
CN202080058199.7A 2019-06-18 2020-06-17 用于治疗炎性病症的方法和组合物 Active CN114258317B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962862977P 2019-06-18 2019-06-18
US62/862,977 2019-06-18
PCT/US2020/038036 WO2020257221A1 (en) 2019-06-18 2020-06-17 Methods and compositions for treating inflammatory conditions

Publications (2)

Publication Number Publication Date
CN114258317A CN114258317A (zh) 2022-03-29
CN114258317B true CN114258317B (zh) 2025-03-14

Family

ID=74040112

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080058199.7A Active CN114258317B (zh) 2019-06-18 2020-06-17 用于治疗炎性病症的方法和组合物

Country Status (6)

Country Link
US (1) US20220313780A1 (https=)
EP (2) EP4461303A3 (https=)
JP (2) JP7818405B2 (https=)
CN (1) CN114258317B (https=)
AU (1) AU2020295989A1 (https=)
WO (1) WO2020257221A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120518705A (zh) * 2025-07-23 2025-08-22 中国海洋大学 一种多肽类化合物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801462A (zh) * 2007-07-13 2010-08-11 健泰科生物技术公司 用于癌症、炎性病症和自身免疫性病症的治疗和诊断
CN104470943A (zh) * 2012-07-03 2015-03-25 一洋药品株式会社 新肽及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965343A (en) 1988-01-28 1990-10-23 Hoffmann-La Roche Inc. Method of peptide synthesis
US5849954A (en) 1996-01-18 1998-12-15 Research Corporation Technologies, Inc. Method of peptide synthesis
US5892014A (en) * 1996-10-30 1999-04-06 The Regents Of The University Of California DNA encoding a protease-activated receptor 3
CN1308671A (zh) * 1998-05-05 2001-08-15 科里克萨公司 髓磷脂碱性蛋白肽及其应用
ATE281472T1 (de) 1999-08-02 2004-11-15 Synt Em Sa Berechnungsmethoden zur herstellung von molekularen mimetika
US7271256B2 (en) 2000-02-04 2007-09-18 New England Biolabs, Inc. Method for producing circular or multimeric protein species in vivo or in vitro and related methods
JP4798921B2 (ja) * 2000-03-06 2011-10-19 バイオシーク インコーポレーティッド 機能相同性スクリーニング
US7696168B2 (en) * 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
FR2841559A1 (fr) * 2002-06-28 2004-01-02 Pfizer Recepteurs par modifies, preparation et utilisations
GB0224013D0 (en) * 2002-10-15 2002-11-27 Oxford Glycosciences Uk Ltd A protein involved in therapy
WO2004056309A2 (en) * 2002-12-05 2004-07-08 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
AU2006242449A1 (en) 2005-04-29 2006-11-09 (Osi) Eyetech, Inc. VEGF variants
US20080090760A2 (en) 2005-12-09 2008-04-17 Todd Hembrough Compositions and Methods for Inhibiting Cellular Proliferation
WO2013070256A2 (en) * 2011-11-07 2013-05-16 The Scripps Research Institute Protease activated receptor-1 (par1) derived cytoprotective polypeptides and related methods
WO2017173346A1 (en) * 2016-04-01 2017-10-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Par3 mimetic peptides and uses thereof
CA3075833C (en) * 2017-09-18 2024-06-11 BH Biotech Pty Ltd Composition comprising withania extract, omega-3 fatty acids and natural product extracts and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801462A (zh) * 2007-07-13 2010-08-11 健泰科生物技术公司 用于癌症、炎性病症和自身免疫性病症的治疗和诊断
CN104470943A (zh) * 2012-07-03 2015-03-25 一洋药品株式会社 新肽及其用途

Also Published As

Publication number Publication date
AU2020295989A1 (en) 2022-01-20
US20220313780A1 (en) 2022-10-06
EP4461303A2 (en) 2024-11-13
JP7818405B2 (ja) 2026-02-20
EP3986560A4 (en) 2023-10-18
JP2022536797A (ja) 2022-08-18
JP2025172264A (ja) 2025-11-21
EP4461303A3 (en) 2025-05-14
EP3986560A1 (en) 2022-04-27
WO2020257221A1 (en) 2020-12-24
CN114258317A (zh) 2022-03-29

Similar Documents

Publication Publication Date Title
JP6568161B2 (ja) 構造化ポリペプチドの特異性のモジュレーション
US20040180823A1 (en) Novel agents that modulate Eph receptor activity
CN112888705A (zh) 蛋白酪氨酸-酪氨酸类似物及其使用方法
US20020147306A1 (en) Peptides that modulate the interaction of B class ephrins and PDZ domains
AU2013262630B2 (en) Huwentoxin-IV variants and methods of use
EP4182023A1 (en) Inhibitors of complement factor c3 and their medical uses
US20110158956A1 (en) Treating cancer
JP2025172264A (ja) 炎症性状態を処置するための方法および組成物
AU2018383633A1 (en) Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive NOXA peptides
Axén et al. Small potent ligands to the insulin‐regulated aminopeptidase (IRAP)/AT4 receptor
JP2008540339A (ja) Ｎｏｇｏレセプター機能モチーフおよびそれに関するペプチド模倣物、ならびにそれらを使用する方法
AU2012272550A1 (en) Prevention and treatment of acute inflammatory conditions
Costantini et al. Peptides targeting chemokine receptor CXCR4: structural behavior and biological binding studies
JP6566947B2 (ja) Ｍａｐキナーゼｐ３８結合化合物
EP1852441A2 (en) Agents that modulate EPH receptor activity
CA2988086C (en) An engineered ccl20 locked dimer polypeptide
US12098175B2 (en) Peptide inhibitors targeting the CXCL12/HMGB1 interaction and uses thereof
US20240101604A1 (en) Selective mena binding peptides
CN121038802A (zh) TNF-α结合剂及其使用方法
Carganico Synthetic modified peptides to reproduce post-translational modifications and structures of pathologically relevant proteins
US20090137484A1 (en) Neuronal Network-Interacting Peptide
Domeniconi Identification of the receptor complex required for inhibition of axonal regeneration by myelin-associated glycoprotein
HK1109904A (en) Agents that modulate eph receptor activity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant